news
-
5 February 2023JenaValve Appoints Dan Dearen to Board of Directors
JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors.
Mr. Dearen has over 35 years of experience in the medical device and pharmaceutical industries and currently serves as President & Chief Financial Officer of Axonics, Inc. Previously, Mr. Dearen was Chief Operating and Financial Officer at Vessix Vascular, leading the integration of Vessix following its acquisition by Boston Scientific. Before that, Mr. Dearen was CFO of several life science and venture capital firms, including Miraval Holding, Q3DM, Fairbanks Systems Group, ESI Software, Medication Delivery Devices, and positions with Ventana Growth Funds.
“We are incredibly pleased to welcome Dan to the JenaValve Board of Directors,” said John Kilcoyne, Chief Executive Officer. “He has a wealth of experience leading healthcare technology companies across development, regulatory, and commercial milestones and advancing the potential of early-stage technologies through successful funding processes. He is also accomplished in implementing short-term and long-term goals to drive value across stakeholders.”
Mr. Dearen earned his B.B.A. in Accounting and Business Management from Southern Methodist University, his M.B.A. in Finance and Strategic Management from Boston College, and his Accredited Director certification from U.C.L.A.
Mr. Dearen stated, “I am honored to join Jenavalve as the company advances its innovative approach to treat patients with symptomatic, severe aortic regurgitation and stenosis, reflecting a multi-billion dollar market opportunity. I have always focused on novel technologies addressing substantial unmet patient needs, and I believe Jenavalve is positioned to change the structural heart landscape for the better. I look forward to adding to the contributions this leadership team and board have driven to-date.”
Related
JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial
JenaValve Raises $100 Million to Advance Trilogy TAVR Solution
Results of First Commercial Trilogy Heart Valve System Implants in EU
JenaValve Appoints Kari Moore as Chief Financial Officer
JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited
JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System
JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial
JenaValve Technology Closes $50 Million Financing
JenaValve Technology Appoints John T. Kilcoyne as Chief Executive Officer
JenaValve Technology Appoints Keith D. Dawkins, M.D., as Board Member
JenaValve Technology Appoints Pieter Van den Steen As Chief Commercial Officer, General Manager
JenaValve Technology Appoints Janet M. Fauls As Vice President Of Regulatory Affairs
JenaValve Announces Certification of New Transcatheter Heart Valve Manufacturing Facility
Jenavalve bags $26.5M to support growth in competitive TAVR market
JenaValve appoints Peter C. Wulff as Chief Financial Officer
JenaValve appoints Victoria E. Carr-Brendel, Ph.D., as Chief Executive Officer
JenaValve appoints Jan Keltjens Interim Chief Executive Officer
JenaValve names Stefan Schreck, Ph.D., Chief Technology Officer
JenaValve names David J. Drachman Chief Executive Officer
JenaValve announces first implantation of Transapical TAVI System in Sweden
JenaValve expands Series C venture financing round
JenaValve Tavi System receives extended CE mark approval for treatment of aortic insufficiency
JenaValve announces first implantation of Transapical Tavi system in Canada